Therefore, the aim of this study was to develop and validate a simple CMR risk score based on data from large, Background-Cardiac magnetic resonance (CMR) demonstrated great potential for the prediction of major adverse cardiac events (MACE) in ST-segment-elevation myocardial infarction. The aim of this study was to develop and validate a CMR-based risk score for ST-segment-elevation myocardial infarction patients. Methods and Results-The scoring model was developed and validated on ST-segment-elevation myocardial infarction cohorts from 2 independent randomized controlled trials (n=738 and n=458 patients, respectively) and included left ventricular (LV) ejection fraction, infarct size, and microvascular obstruction. Primary end point was the 12-month MACE rate consisting of death, reinfarction, and new congestive heart failure. In the derivation cohort, LV ejection fraction ≤47%, infarct size ≥19%LV, and microvascular obstruction ≥1.4%LV were identified as the best cutoff values for MACE prediction. According to the hazard ratios in multivariable regression analysis, the CMR risk score was created by attributing 1 point for LV ejection fraction ≤47%, 1 point for infarct size ≥19%LV, and 2 points for microvascular obstruction ≥1.4%LV. In the validation cohort, the score showed a good prediction of MACE (area under the curve: 0.76). Stratification into a low (0/1 point) and high-risk group (≥2 points) resulted in significantly higher MACE rates in highrisk patients (9.0% versus 2.2%; P=0.001). Inclusion of the CMR score in addition to a model of clinical risk factors led to a significant increase of C statistics from 0.74 to 0.83 (P=0.037), a net reclassification improvement of 0.18 (P=0.009), and an integrated discriminative improvement of 0.04 (P=0.010). Conclusions-Our approach integrates the prognostic information of CMR imaging into a simple risk score that showed incremental prognostic value over clinical risk factors in ST-segment-elevation myocardial infarction patients. Clinical Trial Registration-URL: http://www.clinicaltrials.gov.
D
espite considerable advances in the management of patients with ST-segment-elevation myocardial infarction (STEMI) over the last decades, the risk of future cardiovascular events in STEMI survivors remains substantial. 1 Therefore, research efforts have been directed to identify highrisk patients and develop tools for optimized risk stratification including clinical scores, biomarkers, and multimodality imaging approaches. [2] [3] [4] In recent years, cardiac magnetic resonance (CMR) emerged as the most accurate and feasible noninvasive modality to comprehensively assess functional, morphological, and microvascular alterations after myocardial infarction. Consequently, the prognostic role of CMR imaging was evaluated in multiple studies. Particularly, left ventricular ejection fraction (LVEF) and CMR markers of myocardial and microvascular damage (infarct size [IS] , microvascular obstruction [MO] ) were strongly and independently associated with adverse events after STEMI. [5] [6] [7] [8] [9] [10] [11] Because most of these studies were single-center investigations with relatively small sample sizes and weak combined end points, the impact of CMR parameters on clinical outcome was recently evaluated in an adequately powered multicenter STEMI study with hard clinical end points. 12 The results confirmed the previously reported prognostic implications and expanded the body of evidence by showing incremental value over and above established clinical parameters and LVEF alone. 12 These data underscore the potential of CMR imaging to improve risk stratification in STEMI patients and support an extended use in clinical routine. However, a broad implementation requires incorporation of these prognostic CMR markers in a risk-scoring model which is easy to use and provides clear cutoff values for an increased risk. CMR Risk Score in STEMI multicenter randomized trials in STEMI patients reperfused by primary percutaneous coronary intervention (PCI).
Methods

Study Design and Patient Population
The risk-scoring model was developed on the population of the prospective, multicenter, randomized AIDA STEMI trial (Abciximab Intracoronary Versus Intravenously Drug Application in STEMI) which compared intracoronary versus intravenous abciximab administration in addition to primary PCI in 2065 STEMI patients. 13, 14 The CMR substudy comprised 795 consecutive patients at 8 sites in Germany with proven expertise in CMR imaging. 15 The results showed a similar clinical outcome and no between-group differences about CMR parameters of ischemic injury. The CMR risk score included 3 parameters (LVEF, IS, and MO) which demonstrated prognostic value in a previous investigation based on the AIDA STEMI CMR substudy. 12 The primary aim of the prior analysis was to determine the most potent CMR marker for adverse events (MO), whereas the current study sought to incorporate the prognostic information of all parameters into a single score. Validation of the score was performed in the study population of the prospective, randomized LIPSIA CONDITIONING trial (Cardioprotection by Combined Intrahospital Remote Ischaemic Perconditioning and Postconditioning in STElevation Myocardial Infarction) which randomly assigned 696 STEMI patients undergoing primary PCI in a 1:1:1 ratio to (1) combined intrahospital remote ischemic conditioning+postconditioning in addition to primary PCI, (2) postconditioning in addition to primary PCI, or (3) conventional primary PCI. 16 Combined intrahospital remote ischemic conditioning+postconditioning was associated with improved myocardial salvage, whereas IS, MO, and clinical follow-up did not reveal significant differences between groups. The detailed design and results were published previously. [13] [14] [15] [16] In both studies, patients ≥18 years of age were eligible if their symptoms lasted <12 hours and if they had STsegment elevation of >0.1 mV in ≥2 extremity leads or >0.2 mV in ≥2 adjacent precordial leads. Primary PCI and adjacent medical therapy were performed according to standard clinical practice and guideline recommendations. Both studies were approved by the local ethics committees and complied with the principles of Good Clinical Practice and the Declaration of Helsinki. All patients gave written informed consent.
CMR Image Acquisition and Analysis
By protocol, CMR was performed on days 1 to 10 after the index event on a clinical 1.5-or 3.0-T magnetic resonance scanner. The standardized imaging protocol was identical in both studies and has been described previously. 12, 15 In brief, LV volumes and function were assessed with standard steady-state-free precession technique, T2-weighted triple-inversion recovery turbo spin-echo images were obtained for the determination of edema/myocardium at risk, and T1-weighted inversion recovery turbo gradient-echo sequences ≈15 minutes after intravenous administration of gadolinium-based contrast agent (late gadolinium enhancement images) were used to assess IS and MO. The same contrast agent (gadobutrol; Gadovist/Gadavist, Bayer HealthCare, Berlin, Germany) was used in the participating study centers. All sequences were acquired in continuous stacks of short-axis slices covering the whole LV from base to apex.
Images were analyzed offline at a core laboratory by blinded investigators using certified evaluation software (cmr 42 ; Circle Cardiovascular Imaging Inc, Calgary, Alberta, Canada). Regions of infarcted myocardium and MO were delineated with a semiautomated computer-aided threshold detection (>5 SDs of remote myocardium in ≥10 adjacent myocardial pixels) and expressed as the percentage of LV mass (%LV). If present, MO was included in the overall IS and also quantified separately. The core laboratory has proven excellent reproducibility and low inter-and intraobserver variability (Data Supplement).
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Clinical End Points
The clinical end point was a composite of death, reinfarction, and new congestive heart failure 12 months after STEMI. All components of the clinical end point were adjudicated by an independent clinical events committee. To avoid double counting of patients with >1 event, each patient contributed only once to the composite major adverse cardiovascular events (MACE) end point. Reinfarction was defined as clinical symptoms, new ST-segment changes, and increase in the troponin T level above the reference limit in patients with normalized values or of ≥50% from the last non-normalized measurement. New congestive heart failure was defined as any congestive heart failure (rales, dyspnea, and New York Heart Association class III/IV) occurring >24 hours after the index event.
Statistical Analysis
The CMR risk score was developed on the population of the AIDA STEMI trial in the following steps. The Youden index was calculated to dichotomize the continuous CMR variables (LVEF, IS, and MO) after application of receiver-operating characteristic curves to determine the best cutoff values for MACE prediction. Myocardial salvage index was not included in the model because it accounts for IS by its inclusion in the formula for calculation of myocardial salvage. Subsequently, the scoring system was established after the observed hazard ratios (HRs) in a multivariable Cox regression model. Parameters with a rounded HR of 2 received 1 point and those with a rounded HR of 3 were assigned 2 points. Validation of the score was performed in the LIPSIA CONDITIONING population. Only patients with complete data sets for all CMR variables (LVEF, IS, and MO) were included in the analysis. According to the CMR risk score, the patient populations were classified into a low (0/1 points) and a high (≥2 points) risk group. The primary statistical approach was the comparison of MACE rates between the groups using the Kaplan-Meier method with log-rank testing. HRs were calculated and are reported with corresponding 95% confidence intervals (CIs). Furthermore, χ 2 testing and C statistics were performed to additionally assess the predictive value of the score. Calibration was evaluated in the validation cohort by dividing the patient population into 5 groups and plotting the predicted probability against the observed frequency of 12-month MACE. Hosmer-Lemeshow test was applied to determine goodness of fit. The ability of the CMR risk score to improve risk prediction was evaluated by comparing a baseline logistic regression model containing established clinical risk factors which are part of the Thrombolysis in Myocardial Infarction risk score (age; diabetes mellitus, hypertension, or angina; Killip class 2 to 4; weight; anterior STEMI or left bundle branch block; and time to treatment >4 hours) with a model containing these parameters plus the CMR risk score. C statistics, integrated discriminative improvement, continuous net reclassification improvement (NRI), and categorybased NRI with a cutoff at 3% corresponding to a halving of the 12-month MACE rate were calculated as complementary measures of discrimination performance of constructed models.
In addition, a simplified approach to incorporate the prognostic information of myocardial damage after STEMI was assessed in the validation cohort by stratifying the patient population according to the best cutoff for IS and the presence of MO.
The R packages pROC and PredictABEL were used for C statistics, model calibration, and reclassification analyses. Other analyses were performed with SPSS (version 17.0; SPSS Inc, Chicago, IL). A 2-tailed P value ≤0.05 was considered statistically significant.
Results
Of the 795 patients enrolled in the AIDA STEMI CMR substudy, 57 patients were excluded because of prior myocardial infarction (n=33) or incomplete/insufficient CMR data (n=24; Figure 1 ). For the same reasons, 105 of the 566 patients undergoing CMR imaging in the LIPSIA CONDI-TIONING trial were not included. Consequently, the final derivation cohort consisted of 738 patients, and the validation cohort comprised 461 patients with complete clinical follow-up data in 738 (100%) and 458 (99%) patients, respectively ( Figure 1 ). The 12-month MACE rate in the AIDA STEMI CMR cohort was 7.0% (death, n=20; reinfarction, n=18; new congestive heart failure, n=14). A total of 23 events were observed in the LIPSIA CONDITIONING population (MACE rate 5.0%; death, n=9; reinfarction, n=5; new congestive heart failure, n=9). The main patient characteristics are representative for typical STEMI populations and summarized in Table 1 . All patients underwent CMR imaging in median 3 days (interquartile range, 2-4 days) after infarction in both cohorts.
Derivation of the CMR Risk Score
The following values were identified as the best cutoff points for MACE prediction by Youden index: LVEF ≤47%, IS ≥19%LV, and MO ≥1.4%LV. According to the HR in multivariable Cox regression analysis, the CMR risk score was created by attributing 1 point for LVEF ≤47%, 1 point for IS ≥19%LV, and 2 points for MO ≥1.4%LV, resulting in a score with a minimum of 0 and a maximum of 4 points ( Table 2) . Stratification into 2 risk groups (0/1 versus ≥2 points) classified 463 patients (62.7%) as low risk and 275 patients (37.3%) as high risk. Patients in the high-risk group exhibited a significantly higher 12-month MACE rate compared with low-risk patients (15.3% versus 2.2%; HR, 7.60; 95% CI, 3.81-15.2; P<0.001 by log-rank and χ 2 testing; Figure 2 ). In C statistics, the CMR risk score showed a good prediction of MACE with an area under the curve of 0. 
Validation of the CMR Risk Score
Of the 458 patients with complete follow-up data in the validation cohort, 269 (58.7%) were in the low-risk and 189 (41.3%) in the high-risk group. The observed 12-month MACE rate was 9.0% in high-risk compared with 2.2% in low-risk patients (HR, 2.04; 95% CI, 1.28-3.25; P<0.001 by log-rank and P=0.001 by χ 2 test; Figure 3 ). C statistics revealed a good discrimination with an area under the curve of 0.76 (95% CI, 0.69-0.84). The calibration plot showed that the score was well calibrated (P=0.48 by Hosmer-Lemeshow test for goodness of fit; Figure 4) .
Analysis of the incremental prognostic value of the CMR score is illustrated in Figure 5 . The baseline clinical risk model showed an area under the curve of 0.74 (95% CI, 0.64-0.84). The addition of the CMR score to the baseline model resulted in a significant increase of the C statistics to 0.83 (95% CI, 0.76-0.89; P=0.037). In reclassification analysis applying risk levels of <3% or ≥3%, the inclusion of the CMR risk score led to a category-based NRI of 0.18 (95% CI, 0.04-0.31; P=0.009). In detail, 5% of patients with events and 40% of patients without events were reclassified downward, whereas 33% of cases with events and 10% of cases without events were reclassified upward. The continuous NRI was 0.65 (95% CI, 0.24-1.06; P=0.002) and the integrated discriminative improvement 0.04 (95% CI, 0.01-0.07; P=0.010).
Risk Assessment According to IS and Presence of MO
Stratification of the validation cohort according to IS and presence of MO resulted in 4 groups with the following 12-month MACE rates: IS <19%LV without MO (4/191, 2.1%), IS 
Discussion
This study is the first to incorporate multiple CMR parameters with proven prognostic relevance in STEMI patients into a risk score that exhibits several strengths: (1) development and independent validation in large, well-characterized STEMI 
Risk Stratification in STEMI Patients
Survivors of STEMI face a substantial risk of further cardiovascular events. 1 Therefore, it is important to identify highrisk patients to intervene and potentially prevent these events, which is also emphasized in current guidelines. 18 Several clinical indicators have proven useful for early risk assessment, including older age, elevated heart rate, hypotension, heart failure symptoms (Killip class), anterior infarction, ST-segment resolution, laboratory parameters, and medical history. 19 These factors were combined to various clinical risk scores. 3, 4 However, most of them were developed in the pre-PCI era and advance in cardiac biomarker measurements and imaging techniques enable a more detailed patient evaluation and potentially enhance the predictive accuracy.
Particularly, CMR imaging holds great potential given its unique ability to comprehensively assess the functional and structural changes that occur after STEMI. Cardiac dysfunction can be determined more accurately compared with echocardiography and has been associated with clinical events. 5, 7, 8, 10, 20 Furthermore, high-resolution late gadolinium enhancement imaging allows to visualize and quantify myocardial and microvascular damage relative to the entire LV. The independent and incremental prognostic information of IS and particularly MO in addition to clinical risk scores and LVEF has been shown repeatedly in numerous clinical trials. [5] [6] [7] [8] [9] [10] [11] [12] Consequently, CMR parameters became popular surrogate end points in studies investigating reperfusion success because they allow a reduction of patient numbers and costs. In clinical routine, however, CMR plays a minor role despite the compelling evidence that supports the prognostic value after STEMI. International guidelines recommend CMR imaging (Class IIb; Level of Evidence C) only as an alternative to echocardiography which is considered the reference standard to assess IS and LVEF (Class I; Level of Evidence B). 18 The increase in local experience and availability and the decrease in scanning times to roughly 30 minutes for a postinfarction protocol significantly improved the practicability of CMR imaging. Nevertheless, the variety of different parameters without clearly defined thresholds for increased risk hamper the clinical use of CMR results.
Clinical Applicability of the CMR Risk Score
The present study provides clear cutoff values for 3 established determinants of clinical outcome in STEMI patients and incorporates them into a CMR score, which proved superior risk prediction compared with a baseline model of established clinical risk factors in an independent validation cohort. Quantification of LVEF, IS, and MO can be performed in ≈10 minutes using dedicated evaluation software and assembling the parameters to a single score overcomes the aforementioned drawback because of its easy calculation and interpretation. Therefore, our CMR risk score enables to transfer the prognostic information to patients or physicians without advanced knowledge in CMR imaging which might represent a step toward implementation in clinical routine. However, the question arises whether an increased risk of adverse events carries direct clinical implications for the treatment of the individual patient. Information derived from CMR imaging could influence the length of stay in the coronary care unit and hospital supporting early discharge in low-risk patients. 18 Moreover, accurate quantification of LVEF and the extent of the infarct scar may have the potential to identify patients who are prone to adverse LV remodeling or ventricular arrhythmias. 21 However, any benefit of intensified medical therapy or early device implantation remains speculative in the absence of randomized controlled trials. Likewise, efforts to preserve or improve microvascular perfusion with pharmacological (eg, glycoprotein IIb/IIIa inhibitors) or interventional (eg, thrombus aspiration) strategies did not result in a reduction of clinical events. 13, 15, 22 A more targeted approach rather than routinely treating all STEMI patients might be more appropriate and CMR-guided treatment strategies should be evaluated in future trials.
Future Directions
Although EF is generally considered the reference standard of ventricular function, myocardial strain is the superior index to determine regional and global myocardial function. Recently, several CMR techniques for myocardial strain measurement emerged, similar to speckle-tracking echocardiography. 23, 24 Furthermore, T1-mapping techniques have improved significantly and enable a more detailed tissue characterization compared with late gadolinium enhancement sequences. 25 Preliminary studies investigated the prognostic potential of these novel techniques in STEMI patients and showed promising results. 26, 27 An additional value over and above the established CMR markers that have been used in the present study remains to be proven.
Limitations
The risk-scoring model was developed and validated on the patient populations of large, prospective, randomized trials. 13, 16 Although these studies intended to represent realworld STEMI cohorts, the specific inclusion and exclusion criteria, the treatment in high-volume tertiary care centers, and the obligatory CMR scan might have caused a selection bias. Moreover, patients with previous myocardial infarction were excluded from this analysis. Therefore, the score may not be exactly applicable to these patients and needs further validation in real-world STEMI cohorts. The CMR risk score could not be compared with the Thrombolysis in Myocardial Infarction risk score because heart rate and systolic blood pressure were not assessed in the LIPSIA CON-DITIONING study. However, a clinical model consisting of the remaining parameters was used for comparison. The combined MACE end point included all-cause rather than cardiovascular death because of missing information on the exact causes of death. Overall, a limited number of clinical events were observed within 12 months after infarction in both cohorts. It cannot be excluded that a higher number of adverse events would have changed the prognostic model. CMR imaging was performed on days 1 to 10, which is a wide range in view of novel findings which suggest a time dependency of several parameters after infarction. 28 Standardizing CMR image acquisition and analysis is required given its increasing importance in research and clinical practice.
Conclusions
We used CMR markers of myocardial and microvascular damage to develop and validate a simple score for the prediction of adverse events after STEMI based on data from randomized controlled trials. The CMR risk score is easy to calculate and demonstrated incremental prognostic value over clinical parameters. Therefore, our score integrates the prognostic information of CMR imaging and helps to stratify STEMI patients according to their risk of future adverse events. 
